Notch signaling: Emerging molecular targets for cancer therapy

Research output: Contribution to journalArticle

118 Citations (Scopus)

Abstract

The Notch signaling pathway is a highly conserved developmental pathway, which plays a critical role in cell-fate decision, tissue patterning and morphogenesis. There is increasing evidence that this pathway is dysregulated in a variety of malignancies, and can behave as either an oncogene or a tumor suppressor depending upon cell context. This review highlights the current evidence for aberration of the Notch signaling pathway in a wide range of tumors from hematological cancers, such as leukemia and lymphoma through to skin, breast, lung, pancreas, colon and brain tumors. It proposes that the Notch signaling pathway may represent novel therapeutic targets and will be a welcome asset to the cancer therapeutic arena.

Original languageEnglish
Pages (from-to)690-701
Number of pages12
JournalBiochemical Pharmacology
Volume80
Issue number5
DOIs
StatePublished - Sep 1 2010

Fingerprint

Tumors
Neoplasms
Aberrations
Brain
Skin
Therapeutics
Tissue
Morphogenesis
Oncogenes
Brain Neoplasms
Pancreas
Lymphoma
Colon
Leukemia
Breast
Lung

Keywords

  • Cancer therapeutics
  • Notch
  • Signal transduction
  • Tumor
  • Tumor angiogenesis

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry

Cite this

Notch signaling : Emerging molecular targets for cancer therapy. / Yin, Ling; Velazquez, Omaida C; Liu, Zhao-Jun.

In: Biochemical Pharmacology, Vol. 80, No. 5, 01.09.2010, p. 690-701.

Research output: Contribution to journalArticle

@article{8d0f5e671e464605940d0ad3f2aebfe0,
title = "Notch signaling: Emerging molecular targets for cancer therapy",
abstract = "The Notch signaling pathway is a highly conserved developmental pathway, which plays a critical role in cell-fate decision, tissue patterning and morphogenesis. There is increasing evidence that this pathway is dysregulated in a variety of malignancies, and can behave as either an oncogene or a tumor suppressor depending upon cell context. This review highlights the current evidence for aberration of the Notch signaling pathway in a wide range of tumors from hematological cancers, such as leukemia and lymphoma through to skin, breast, lung, pancreas, colon and brain tumors. It proposes that the Notch signaling pathway may represent novel therapeutic targets and will be a welcome asset to the cancer therapeutic arena.",
keywords = "Cancer therapeutics, Notch, Signal transduction, Tumor, Tumor angiogenesis",
author = "Ling Yin and Velazquez, {Omaida C} and Zhao-Jun Liu",
year = "2010",
month = "9",
day = "1",
doi = "10.1016/j.bcp.2010.03.026",
language = "English",
volume = "80",
pages = "690--701",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Notch signaling

T2 - Emerging molecular targets for cancer therapy

AU - Yin, Ling

AU - Velazquez, Omaida C

AU - Liu, Zhao-Jun

PY - 2010/9/1

Y1 - 2010/9/1

N2 - The Notch signaling pathway is a highly conserved developmental pathway, which plays a critical role in cell-fate decision, tissue patterning and morphogenesis. There is increasing evidence that this pathway is dysregulated in a variety of malignancies, and can behave as either an oncogene or a tumor suppressor depending upon cell context. This review highlights the current evidence for aberration of the Notch signaling pathway in a wide range of tumors from hematological cancers, such as leukemia and lymphoma through to skin, breast, lung, pancreas, colon and brain tumors. It proposes that the Notch signaling pathway may represent novel therapeutic targets and will be a welcome asset to the cancer therapeutic arena.

AB - The Notch signaling pathway is a highly conserved developmental pathway, which plays a critical role in cell-fate decision, tissue patterning and morphogenesis. There is increasing evidence that this pathway is dysregulated in a variety of malignancies, and can behave as either an oncogene or a tumor suppressor depending upon cell context. This review highlights the current evidence for aberration of the Notch signaling pathway in a wide range of tumors from hematological cancers, such as leukemia and lymphoma through to skin, breast, lung, pancreas, colon and brain tumors. It proposes that the Notch signaling pathway may represent novel therapeutic targets and will be a welcome asset to the cancer therapeutic arena.

KW - Cancer therapeutics

KW - Notch

KW - Signal transduction

KW - Tumor

KW - Tumor angiogenesis

UR - http://www.scopus.com/inward/record.url?scp=77954215506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954215506&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2010.03.026

DO - 10.1016/j.bcp.2010.03.026

M3 - Article

C2 - 20361945

AN - SCOPUS:77954215506

VL - 80

SP - 690

EP - 701

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 5

ER -